Karolinska Institute scientists have attacked glioblastoma multiforme by inducing an unconventional cell death pathway involving catastrophic vacuolization. The team identified a small molecule that prolonged survival in mouse GBM, but a combination approach with a conventional anticancer agent will likely be necessary in the clinic.